Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Hallager, S, Ladelund, S, Kjaer, MS, Madsen, LG, Belard, E, Laursen, AL, Gerstoft, J, Røge, BT, Grønbaek, KE, Krarup, HB, Christensen, PB & Weis, N 2018, 'Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study' Journal of Viral Hepatitis, bind 25, nr. 1, s. 47-55. https://doi.org/10.1111/jvh.12764

APA

CBE

MLA

Vancouver

Author

Hallager, Sofie ; Ladelund, Steen ; Kjaer, Mette S ; Madsen, Lone G ; Belard, Erika ; Laursen, Alex Lund ; Gerstoft, Jan ; Røge, Birgit Thorup ; Grønbaek, Karin E ; Krarup, Henrik Bygum ; Christensen, Peer B. ; Weis, Nina. / Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark : a nationwide cohort study. I: Journal of Viral Hepatitis. 2018 ; Bind 25, Nr. 1. s. 47-55.

Bibtex

@article{5fcecfd566ae43efbdddba3b14409985,
title = "Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study",
abstract = "Cirrhosis in patients with chronic hepatitis C increases the risk of hepatocellular carcinoma (HCC) and surveillance with ultrasound (US) and alpha-fetoprotein (AFP) is recommended. This study aimed to estimate changes in the HCC incidence rate (IR) over time, HCC stage and prognosis, and AFP and US performed in patients with hepatitis C and cirrhosis. Eligible patients were identified in the Danish Database for Hepatitis B and C and data from national health registries and patient charts were obtained. Tumor stage was based on Barcelona-Clinic Liver Cancer stage, TNM classification and size and number of lesions combined into stage 0 - 3. We included 1,075 patients with hepatitis C and cirrhosis, free of HCC and liver transplant at baseline. During 4,988 person years (PY) 115 HCC cases were diagnosed. The HCC incidence rate increased from 0.8/100 PY [CI95{\%} 0.4 - 1.5] in 2002-2003 to 2.9/100 PY [2.4 - 3.4] in 2012-2013. One-year cumulative incidence of at least one AFP or US was 53{\%} among all patients. The positive predictive value of an AFP ≥ 20 ng mL(-1) was 17{\%}. Twenty-three (21{\%}) patients were diagnosed with early stage HCC (stage 0/1) and 84 (79{\%}) with late stage. Median survival after HCC for early stage HCC disease was 30.1 months and 7.4 months for advanced HCC (stage 2/3). The incidence rate of HCC increased over time among patients with hepatitis C and cirrhosis in Denmark. Application of AFP and US was suboptimal and most patients were diagnosed with advanced HCC with a poor prognosis. This article is protected by copyright. All rights reserved.",
keywords = "Journal Article",
author = "Sofie Hallager and Steen Ladelund and Kjaer, {Mette S} and Madsen, {Lone G} and Erika Belard and Laursen, {Alex Lund} and Jan Gerstoft and R{\o}ge, {Birgit Thorup} and Gr{\o}nbaek, {Karin E} and Krarup, {Henrik Bygum} and Christensen, {Peer B.} and Nina Weis",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "1",
doi = "10.1111/jvh.12764",
language = "English",
volume = "25",
pages = "47--55",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark

T2 - a nationwide cohort study

AU - Hallager, Sofie

AU - Ladelund, Steen

AU - Kjaer, Mette S

AU - Madsen, Lone G

AU - Belard, Erika

AU - Laursen, Alex Lund

AU - Gerstoft, Jan

AU - Røge, Birgit Thorup

AU - Grønbaek, Karin E

AU - Krarup, Henrik Bygum

AU - Christensen, Peer B.

AU - Weis, Nina

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/1

Y1 - 2018/1

N2 - Cirrhosis in patients with chronic hepatitis C increases the risk of hepatocellular carcinoma (HCC) and surveillance with ultrasound (US) and alpha-fetoprotein (AFP) is recommended. This study aimed to estimate changes in the HCC incidence rate (IR) over time, HCC stage and prognosis, and AFP and US performed in patients with hepatitis C and cirrhosis. Eligible patients were identified in the Danish Database for Hepatitis B and C and data from national health registries and patient charts were obtained. Tumor stage was based on Barcelona-Clinic Liver Cancer stage, TNM classification and size and number of lesions combined into stage 0 - 3. We included 1,075 patients with hepatitis C and cirrhosis, free of HCC and liver transplant at baseline. During 4,988 person years (PY) 115 HCC cases were diagnosed. The HCC incidence rate increased from 0.8/100 PY [CI95% 0.4 - 1.5] in 2002-2003 to 2.9/100 PY [2.4 - 3.4] in 2012-2013. One-year cumulative incidence of at least one AFP or US was 53% among all patients. The positive predictive value of an AFP ≥ 20 ng mL(-1) was 17%. Twenty-three (21%) patients were diagnosed with early stage HCC (stage 0/1) and 84 (79%) with late stage. Median survival after HCC for early stage HCC disease was 30.1 months and 7.4 months for advanced HCC (stage 2/3). The incidence rate of HCC increased over time among patients with hepatitis C and cirrhosis in Denmark. Application of AFP and US was suboptimal and most patients were diagnosed with advanced HCC with a poor prognosis. This article is protected by copyright. All rights reserved.

AB - Cirrhosis in patients with chronic hepatitis C increases the risk of hepatocellular carcinoma (HCC) and surveillance with ultrasound (US) and alpha-fetoprotein (AFP) is recommended. This study aimed to estimate changes in the HCC incidence rate (IR) over time, HCC stage and prognosis, and AFP and US performed in patients with hepatitis C and cirrhosis. Eligible patients were identified in the Danish Database for Hepatitis B and C and data from national health registries and patient charts were obtained. Tumor stage was based on Barcelona-Clinic Liver Cancer stage, TNM classification and size and number of lesions combined into stage 0 - 3. We included 1,075 patients with hepatitis C and cirrhosis, free of HCC and liver transplant at baseline. During 4,988 person years (PY) 115 HCC cases were diagnosed. The HCC incidence rate increased from 0.8/100 PY [CI95% 0.4 - 1.5] in 2002-2003 to 2.9/100 PY [2.4 - 3.4] in 2012-2013. One-year cumulative incidence of at least one AFP or US was 53% among all patients. The positive predictive value of an AFP ≥ 20 ng mL(-1) was 17%. Twenty-three (21%) patients were diagnosed with early stage HCC (stage 0/1) and 84 (79%) with late stage. Median survival after HCC for early stage HCC disease was 30.1 months and 7.4 months for advanced HCC (stage 2/3). The incidence rate of HCC increased over time among patients with hepatitis C and cirrhosis in Denmark. Application of AFP and US was suboptimal and most patients were diagnosed with advanced HCC with a poor prognosis. This article is protected by copyright. All rights reserved.

KW - Journal Article

U2 - 10.1111/jvh.12764

DO - 10.1111/jvh.12764

M3 - Journal article

VL - 25

SP - 47

EP - 55

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 1

ER -

ID: 51518682